OncoMatch/Clinical Trials/NCT06771544
Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma
Is NCT06771544 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Pembrolizumab and Cyclophosphamide for melanoma.
Treatment: Pembrolizumab · Cyclophosphamide — This is a phase 2, single-arm, open label clinical trial determining efficacy of Cyclophosphamide and Pembrolizumab in subjects with melanoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Cancer type
Melanoma
Biomarker criteria
Allowed: BRAF driver mutation
Disease stage
Required: Stage III, IV
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: anti-PD-1 therapy
Has progressed on a prior PD-1/PD-L1 treatment
Cannot have received: BRAF inhibitor
Exception: allowed if patient declines or is unable to tolerate BRAF and/or MEK inhibitors
Presence of B-RAF driver mutation without prior receipt of BRAF +/- MEK inhibitors, unless patient declines BRAF +/-MEK inhibition for any reason or is unable to tolerate BRAF and/or MEK inhibitors.
Cannot have received: allogeneic tissue/solid organ transplant
Participants with a history of allogeneic tissue/solid organ transplant
Cannot have received: any prior investigational or standard cancer therapy (except PD-1/PD-L1, chemotherapy or radiation within 6-9 weeks of first dose)
Exception: PD-1/PD-L1, chemotherapy, or radiation allowed if outside 6-9 week window
Any prior investigational or standard cancer therapy, with exception of PD-1/PD-L1 (includes nivolumab + Relatlimab) therapy, chemotherapy or radiation within 6-9 weeks of the first dose of the investigational therapy
Lab requirements
Blood counts
Hemoglobin ≥9.0 g/dL; Platelets ≥100/mm3; ANC ≥1.5/mm3; Albumin < 3.0 g/dL is exclusionary; Absolute lymphocyte count < 0.5 × 10^9/L is exclusionary
Kidney function
Creatinine Clearance ≥ 30mL/min Cockcroft-Gault; Glomerular filtration rate < 30 mL/min is exclusionary
Liver function
AST and ALT less than 3 times the Upper Limit of Normal or less than 5 times the Upper Limit of normal with liver metastases. T Bilirubin < 3.1 mg/dL.
Adequate bone marrow, liver, and renal function; Hemoglobin ≥9.0 g/dL; Platelets ≥100/mm3; ANC ≥1.5/mm3; Creatinine Clearance ≥ 30mL/min Cockcroft-Gault; AST and ALT less than 3 times the Upper Limit of Normal or less than 5 times the Upper Limit of normal with liver metastases. T Bilirubin < 3.1 mg/dL.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Chao Family Comprehensive Cancer Center University of California, Irvine · Orange, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06771544 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior BRAF inhibitor, allogeneic tissue/solid organ transplant, any prior investigational or standard cancer therapy (except PD-1/PD-L1, chemotherapy or radiation within 6-9 weeks of first dose) disqualifies patients from enrollment.
What disease stage is eligible?
Stage III or IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages